GU Cancers Symposium 2014 - Everolimus as second-line therapy for metastatic renal cell carcinoma after one previous VEGF-targeted therapy: Final results of the noninterventional change study - Poster

SAN FRANCISCO, CA USA (UroToday.com) - Presented by Peter J. Goebell, Ulrich Kube, Michael Staehler, Christian Doehn, Thomas Steiner, Manfred Kindler, Edwin Herrmann, Jan Janssen, Steffen Weikert, Michael Thomas Scheffler, Joerg Schmitz, Friedrich Overkamp, Gernot Guderian, Michael Albrecht, and Lothar Bergmann at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

gucancer 2014 goebell Poster thumb

Department of Urology, Friedrich-Alexander University Erlangen, Erlangen, Germany; Private Practice for Oncology, Chemnitz, Germany; Department of Urology, University of Munich, Munich, Germany; Urologikum Lübeck, Lübeck, Germany; Helios-Klinikum Erfurt, Klinik für Urologie, Erfurt, Germany; Private Practice for Oncology, Berlin, Germany; Department of Urology, University of Münster, Münster, Germany; Private Practice for Oncology, Westerstede, Germany; Charité Campus Mitte, Berlin, Germany; Praxis Dr. Scheffler, Zwickau, Germany; Kliniken der Stadt Köln Merheim, Cologne, Germany; Praxis und Tagesklinik für Internistische Onkologie, Recklinghausen, Germany; Novartis Pharma GmbH, Nuermberg, Germany; Department Drug Safety & Epidemiology, Novartis Pharma GmbH, Nuremberg, Germany; Klinikum der Johann-Wolfgang-Goethe Universität, Medizinische Klinik III, Tumorzentrum Rhein-Main,, Frankfurt/Main, Germany

 

APCCC 2021 read now


email news signup